Best Value Marijuana Stocks . Create a list of the investments you want to track. 4.4 out of 5 stars with 23 reviews. Cannabis extraction company Halo Labs Inc. (NEO: HALO) (OTCQX:AGEEF) opted to acquire a debt of $18.44 million owed to Evolution Trustees Ltd., a … For HALO, shares are up 1.54% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 0.58% over the same time period. Halo Top is light ice cream that actually tastes like ice cream. In terms of its 52-week price range, HALO has a high of $41.55 and a low of $12.71. Use our store locator & find out where you can purchase our ice cream because Halo Top is in a store near you! Long term indicators on average place the stock in the category of 100% Buy. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Sort by Featured. Dollar Weakened Against Euro, Manufacturing Growth Also Remain Slow In U.S. Dollar Fell, Investors Waiting Fed Coming To A Definite Decision, U.S. To Mass Vaccinate In 2021, But 58% Are Willing. Include out of stock. Include out of stock. These are the marijuana stocks with the lowest 12-month trailing price-to-sales (P/S) ratio. There are currently no items in this Watchlist. For a wide assortment of Halo Top visit Target.com today. More About Halozyme Therapeutics, Inc. Over the past year the S&P 500 is higher by 13.98% while HALO is higher by 98.17%. None analyst(s) rate it as outperform while none of them rated it as underperform, whereas 1 suggest the stock as a Sell. Halozyme Therapeutics, Inc. Common Stock (HALO) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. HALO Stock Summary.
Choose from contactless Same Day Delivery, Drive Up and more. 99 View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Halo Top Chocolate Chip Frozen Cookie Dough - 1pt. A high-level overview of Halozyme Therapeutics, Inc. (HALO) stock. The company has a trailing 12-month PE ratio of 265.42. Post-Market 0.00 (0.00%) The President & CEO of Halozyme is Exercising Options, A Director at Halozyme (HALO) is Selling Shares, Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer, Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval, Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology, Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion, Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy, Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate, Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study, Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed, J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination, Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus, Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut, Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses, Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus. The median projection represents growth adding up to 121.1% compared to sales growth for the corresponding quarter a year ago. Best-in-Class Portfolio Monitoring. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the HALO stock to lose ahead of the earnings release. Stock Ideas and Recommendations. Halozyme Therapeutics, Inc. (HALO) stock is trading at $27.84 as of 2:14 PM on Thursday, Sep 3, a decline of -$0.67, or -2.35% from the previous closing price of $28.51. Get Ready for my next COVID-19 stock idea. The average price target for the stock over the next 12 months is $40.4, with the estimates having a low of $15 and a high of $60. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. The data shows that short shares as of November 12, 2020, stood at 14.6 Million at a short ratio of 4.72. Log in to see them here or sign up to get started. Delicious healthy ice cream. This represents a 10.8% short interest in shares outstanding on November 12, 2020. View More Companies. For the best MarketWatch.com experience, please update to a modern browser. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2020 is expected to hit $264.56 Million, or +35% up from figures reported last year. >> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<, Join now to get the Stocksregister.com pre-market morning brief 100% free. Our goal for our members is to get our Alert’s first before the crowd.